Search results
Showing 1 to 10 of 10 results for galcanezumab
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Awaiting development [GID-TA11311] Expected publication date: TBC
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
Discontinued [GID-TA10425]
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
145,000 people in England to have further treatment choice for preventing migraine attacks.
NICE has for the first time recommended an oral treatment for preventing migraines.